Sam Brusco, Associate Editor03.07.24
SurGenTec has announced the first implantations and U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoFlo HydroPutty synthetic bone graft.
OsteoFlo HydroPutty features a combination of proprietary hydrophilic carriers to absorb fluids like bone marrow aspirate, blood, or saline. The formulation turns into a putty for improved handling with a resorption profile optimized for bone growth.
The putty is supplied in a sterile vial as a dry formulation with a mixing spatulas. After adding fluid, the hydrophilic bonds quickly absorb the desired fluid to form the putty. The product can be packed into void, resists, irrigation, and can be delivered through the company’s Graftgun bone graft delivery system.
The fully synthetic bone graft option minimizes risks associated with human tissue. The company said short-term and long-term preclinical studies demonstrated excellent bone growth and integration at all time points.
SurGenTec founder and CEO Travis Greenhalgh said: "We are thrilled to add OsteoFlo HydroPutty to our portfolio. Its unique hydrophilic bonds enable the attachment of growth factors and provide an ideal scaffolding for bone growth. This product underscores our commitment to developing next-generation solutions for physicians and patients."
In October 2023, the company introduced its TiLink-P minimally invasive compression implant for chronic sacroiliac (SI) joint pain.
OsteoFlo HydroPutty features a combination of proprietary hydrophilic carriers to absorb fluids like bone marrow aspirate, blood, or saline. The formulation turns into a putty for improved handling with a resorption profile optimized for bone growth.
The putty is supplied in a sterile vial as a dry formulation with a mixing spatulas. After adding fluid, the hydrophilic bonds quickly absorb the desired fluid to form the putty. The product can be packed into void, resists, irrigation, and can be delivered through the company’s Graftgun bone graft delivery system.
The fully synthetic bone graft option minimizes risks associated with human tissue. The company said short-term and long-term preclinical studies demonstrated excellent bone growth and integration at all time points.
SurGenTec founder and CEO Travis Greenhalgh said: "We are thrilled to add OsteoFlo HydroPutty to our portfolio. Its unique hydrophilic bonds enable the attachment of growth factors and provide an ideal scaffolding for bone growth. This product underscores our commitment to developing next-generation solutions for physicians and patients."
In October 2023, the company introduced its TiLink-P minimally invasive compression implant for chronic sacroiliac (SI) joint pain.